128 related articles for article (PubMed ID: 33741812)
1. Extreme elevation of acute phase reactants and shock secondary to dabrafenib-trametinib.
Ayala de Miguel P; Gorospe García I; López Gallego J; Borrega García P
Melanoma Res; 2021 Jun; 31(3):268-271. PubMed ID: 33741812
[TBL] [Abstract][Full Text] [Related]
2. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Casey M; Ouellet D; Martin AM; Le N; Patel K; Flaherty K
N Engl J Med; 2014 Nov; 371(20):1877-88. PubMed ID: 25265492
[TBL] [Abstract][Full Text] [Related]
3. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.
Schadendorf D; Robert C; Dummer R; Flaherty KT; Tawbi HA; Menzies AM; Banerjee H; Lau M; Long GV
Eur J Cancer; 2021 Aug; 153():234-241. PubMed ID: 34225229
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
6. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
Flaherty KT; Infante JR; Daud A; Gonzalez R; Kefford RF; Sosman J; Hamid O; Schuchter L; Cebon J; Ibrahim N; Kudchadkar R; Burris HA; Falchook G; Algazi A; Lewis K; Long GV; Puzanov I; Lebowitz P; Singh A; Little S; Sun P; Allred A; Ouellet D; Kim KB; Patel K; Weber J
N Engl J Med; 2012 Nov; 367(18):1694-703. PubMed ID: 23020132
[TBL] [Abstract][Full Text] [Related]
7. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
[TBL] [Abstract][Full Text] [Related]
8. Facing the challenges of new melanoma-targeted therapies: Treatment of severe fevers associated with dabrafenib/trametinib combination therapy.
Lindsay JN; Barras M
J Oncol Pharm Pract; 2015 Aug; 21(4):293-5. PubMed ID: 24664475
[TBL] [Abstract][Full Text] [Related]
9. Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: Case report.
Sundaram VR; Abbas T
Medicine (Baltimore); 2018 Nov; 97(44):e12751. PubMed ID: 30383630
[TBL] [Abstract][Full Text] [Related]
10. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.
Menzies AM; Ashworth MT; Swann S; Kefford RF; Flaherty K; Weber J; Infante JR; Kim KB; Gonzalez R; Hamid O; Schuchter L; Cebon J; Sosman JA; Little S; Sun P; Aktan G; Ouellet D; Jin F; Long GV; Daud A
Ann Oncol; 2015 Feb; 26(2):415-21. PubMed ID: 25411413
[TBL] [Abstract][Full Text] [Related]
12. Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study.
Huynh S; Lheure C; Franck N; Goldman-Lévy G; Aractingi S; Dupin N; Kramkimel N; Guégan S
Melanoma Res; 2020 Jun; 30(3):317-320. PubMed ID: 32053122
[TBL] [Abstract][Full Text] [Related]
13. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
14. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
Lacroix JP; Wang B
J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
[TBL] [Abstract][Full Text] [Related]
15. Dabrafenib plus trametinib in patients with BRAF
Subbiah V; Lassen U; Élez E; Italiano A; Curigliano G; Javle M; de Braud F; Prager GW; Greil R; Stein A; Fasolo A; Schellens JHM; Wen PY; Viele K; Boran AD; Gasal E; Burgess P; Ilankumaran P; Wainberg ZA
Lancet Oncol; 2020 Sep; 21(9):1234-1243. PubMed ID: 32818466
[TBL] [Abstract][Full Text] [Related]
16. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
17. Apparent darkening of scalp hair related to pili multigemini Following dabrafenib and trametinib.
Avila C; Hoffman K; Milani-Nejad N; Pootrakul L
Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155032
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of neutrophil and C-reactive protein reflect the clinical course of pyrexia during combination therapy with dabrafenib and trametinib.
Maeda T; Yoshino K; Yamashita C; Nagai K; Oaku S; Kato M; Hiura A; Uehara J; Fujisawa Y
J Dermatol; 2019 Aug; 46(8):716-719. PubMed ID: 31180164
[TBL] [Abstract][Full Text] [Related]
19. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
Johnson DB; Flaherty KT; Weber JS; Infante JR; Kim KB; Kefford RF; Hamid O; Schuchter L; Cebon J; Sharfman WH; McWilliams RR; Sznol M; Lawrence DP; Gibney GT; Burris HA; Falchook GS; Algazi A; Lewis K; Long GV; Patel K; Ibrahim N; Sun P; Little S; Cunningham E; Sosman JA; Daud A; Gonzalez R
J Clin Oncol; 2014 Nov; 32(33):3697-704. PubMed ID: 25287827
[TBL] [Abstract][Full Text] [Related]
20. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
